For the year ending 2025-12-31, ATRC had $44,707K increase in cash & cash equivalents over the period. $48,284K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,448 |
| Share-based compensation expense | 44,685 |
| Depreciation | 12,090 |
| Amortization of intangible assets | 8,441 |
| Amortization of deferred financing costs | 478 |
| Amortization of investments | 0 |
| Acquired in-process research and development expense | 6,000 |
| Loss on debt extinguishment | 0 |
| Other non-cash adjustments | 1,374 |
| Accounts receivable | 5,610 |
| Inventories | 2,256 |
| Other current assets | 328 |
| Accounts payable | -960 |
| Accrued liabilities | 6,997 |
| Other noncurrent assets and liabilities | 2,129 |
| Net cash provided by operating activities | 57,334 |
| Sales and maturities of available-for-sale securities | 0 |
| Purchases of property and equipment | 9,050 |
| Proceeds from sale of property and equipment | 0 |
| Acquisitions, including in-process research and development | 6,000 |
| Proceeds from capital grant | 500 |
| Net cash (used in) provided by investing activities | -14,550 |
| Proceeds from revolving credit facility, net of financing costs | 0 |
| Payments on debt, leases and financing obligation | 1,201 |
| Proceeds from financing obligation | 6,250 |
| Payment of financing costs and bank fees | 0 |
| Proceeds from stock option exercises | 1,367 |
| Shares repurchased for payment of taxes on stock awards | 11,163 |
| Proceeds from issuance of common stock under employee stock purchase plan | 5,923 |
| Net cash provided by (used in) financing activities | 1,176 |
| Effect of exchange rate changes on cash and cash equivalents | 747 |
| Net increase in cash and cash equivalents | 44,707 |
| Cash and cash equivalentsbeginning of period | 122,721 |
| Cash and cash equivalentsend of period | 167,428 |
AtriCure, Inc. (ATRC)
AtriCure, Inc. (ATRC)